BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

HiRO forges strategic partnership with CHA University Bundang Medical Center in South Korea

December 16, 2024 | News

For delivering comprehensive solutions to global biotech and pharmaceutical companies across Phase I through Phase IV clinical trials



Harvest Integrated Research Organization (HiRO), a boutique global clinical research organization (CRO) providing cross-border clinical trial solutions, has signed a Memorandum of Understanding (MoU) with CHA University Bundang Medical Center (CBMC), a renowned medical institution in Seoul, South Korea.

In this strategic partnership, HiRO and CBMC are set to closely collaborate, delivering comprehensive solutions to global biotech and pharmaceutical companies across Phase I through Phase IV clinical trials.

By leveraging their collective expertise, HiRO and CBMC are dedicated to streamlining clinical trial processes for optimal efficiency, fostering innovation, and driving advancements in healthcare research in the region and globally.

As a flagship hospital of the CHA Medical Group, one of South Korea's largest biomedical groups, CBMC is distinguished for its state-of-the-art medical services and robust research capabilities. CBMC's collaboration with HiRO will focus on providing valuable insights and support for clinical trials conducted at the center, spanning critical areas such as feasibility assessments, principal investigator selection, and the facilitation of patient recruitment processes. Correspondingly, HiRO will actively showcase the clinical research capabilities of South Korea and CBMC on global platforms, highlighting the exceptional facilities, skilled professionals, and research excellence of the region and the center.

Dr Young-Sang Kim, Director of CHA Global Clinical Trials Center, underscored the significance of the collaboration, expressed, "Drawing on HiRO's presence across the US, Europe, and the Asia-Pacific region, we are reinforcing our commitment to providing more effective and pioneering treatments on a global scale, ultimately improving outcomes for patients in need."